MAPT and Alzheimer disease: Besides the two last popular AD hallmarks, recent data suggest that the fractalkine ligand and its microglial receptor (CX3CL1/CX3CR1) can influence pathologies related to tau by controlling microglial migration and attracting monocytes to the brain.53